Generic injectables-focused company Gland Pharma is looking to raise ~₹ 6,480 crores through capital markets.
Gland Pharma Ltd, Hyderabad based primarily B2B pharma company having seven manufacturing facilities in India
During FY20, Gland pharma generated 66.7% revenues from USA, 17.7% revenues from India and balance from rest of the world
IPO issue would start for subscription on 9-Nov-20 till 11-Oct-20 with price band of ₹ 1,490 to ₹ 1,500 per share.
Hyderabad based Pharma company incorporated in March 1978 as Gland Pharma Private Limited and subsequently renamed as Gland Pharma Limited. Promoters of the company are Fosun Singapore and Shanghai Fosun Pharma.
Through this IPO, Gland Pharma is looking to raise ₹ 6,280 Crores primarily for 1) Funding incremental working capital requirements of our Company; 2) Funding capital expenditure requirements of our Company; and 3) General corporate purposes.
Gland Pharma has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities. Its centralised R&D laboratory is located at manufacturing facility at Dundigal, Hyderabad
Promoters of Gland pharma are Fosun Singapore and Shanghai Fosun Pharma. Fosun Singapore holds 114,662,620 Equity Shares, including 10 Equity Shares each held by Fosun Industrial Co., Limited, Ample Up Limited, Regal Gesture Limited and Lustrous Star Limited for the benefit of Fosun Singapore, which aggregates to 74.00% of the pre-Offer, issued, subscribed and paid-up Equity Share capital of our Company. Shanghai Fosun Pharma holds 100% of the share capital of Fosun Industrial Co., Limited, which holds 100% of the share capital of Fosun Singapore. Shanghai Fosun Pharma does not directly hold any of the pre-Offer, issued, subscribed and paid-up Equity Share capital of our Company
Gland Pharma is manufacturing following pharma product categories:
- Anti-diabetic
- Anti-infectives
- Anti-malarials
- Anti-neoplastics
- Blood-related
- Cardiac
- Gastro-intestinal
- Hormones
- Neurological and central nervous system
- Ophthalmics and otologicals
- Pain, neuro-muscular blocking agents and analgesics
- Respiratory
- Vitamins, minerals and nutrients and others
Key Pointers
- 267 ANDA filings in the United States, of which 215 were approved and 52 were pending approval.
- 267 ANDA filings comprise 191 ANDA filings for sterile injectables, 50 for oncology and 26 for ophthalmics related products.
- 1,427 product registrations, comprising 371 product registrations in the United States, Europe, Canada and Australia, 54 in India and 1,002 in the Rest of the world
- All Gland Pharma's facilities are approved by the USFDA from whom we have had no warning letters since the inception of each facility.
- Other key regulatory agencies for which certain of our facilities have approvals include MHRA (UK), TGA (Australia), ANVISA (Brazil), AGES (Austria) and BGV Hamburg (Germany).
- During FY20, Gland pharma generated 66.7% revenues from USA, 17.7% revenues from India, 4.4% revenues from Europe, 1.8% revenues from Canada 0.5% revenues from Australia and 8.8% revenues from Rest of the world.
Key Management
| Yiu Kwan Stanley Lau | Chairman |
| Srinivas Sadu | MD & CEO |
| Ravi Shekhar Mitra | CFO |
| Susheel Ogra | Senior General Manager Sales & Marketing |
| Ashish Adhikari | VP-Operations |
| P. Sampath Kumar | CS & Compliance Officer |
Gland Pharma IPO Snapshot
| Issue Open | 9-Nov-2020 |
| Issue Close | 11-Nov-2020 |
| Face Value | ₹ 1/- |
| Price Band | ₹ 1,490 to ₹ 1,500 (Including premium of ₹ 1,489 to ₹ 1,499 per share) |
| Discount | Nil |
| Bid Lot | 10 shares and in mutiples |
| Listing on | BSE and NSE |
| Mode of Payment | UPI / ASBA (Mandatory); Applications using third party UPI/ASBA Bank accounts are liable to rejected |
Gland Pharma Issue & Subscribed Details
| Particulars | Issued | Subscribed |
|---|---|---|
| Issue Size | ₹ 6,479.5 Crores (Upper Band) | ₹ - Crores |
| QIB Portion | ~50% | TBA times |
| NII Portion (Application for lot size of 15 & above) | ~15% | TBA times |
| Retail Portion (Applications for lot size between 1 & upto 15) | ~35% | TBA times |
| Employees Portion | NA | NA |
| Total | 100% | TBA times |
Gland Pharma Indicative Dates
| Issue Open | 9-Nov-2020 |
| Issue Close | 11-Nov-2020 |
| Anchor Investor Bidding | One working day prior to Issue opening date 6-Nov-2020 |
| Announcement of Allotment | 17-Nov-2020 |
| Initiation of Refunds | 18-Nov-2020 |
| Credit of Shares | 19-Nov-2020 |
| Listing | 20-Nov-2020 |
Lead Managers of Gland Pharma IPO
List of Book Running and Lead/Co-Lead Manager/s
| Kotak Mahindra Capital Company Ltd. |
| Citigroup Global Markets India Private Limited |
| Haitong Securities India Private Limited |
| Nomura Financial Advisory and Securities (India) Private Limited |
Registrar of Gland Pharma IPO
| Link Intime India Private Limited |
Valuation
Company is looking at the following valuation
| Issue Size | ₹ 6,479.5 Crores (Upper Band |
| Pre-Issue Promoter's Holding | % |
| Post Issue Promoter's Holding | % |
| Pre-Issue Shares | ₹ 154.95 Crores |
| Post Issue Shares | ₹- Crores |
| Post Issue Market Cap (based on Price band) | ₹ to ₹ Crores |
Address of Gland Pharma IPO
| Name | Gland Pharma Ltd. |
| Corporate Identity Number | U24239TG1978PLC002276 |
| Contact Person | Sampath Kumar Pallerlamudi, Company Secretary and Compliance Officer |
| Registered and Corporate Office | Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally, Dundigal, Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India; Tel: +91 40 3051 0999 |
| Website | www.glandpharma.com |
| investors@glandpharma.com |
Check Allotment Status of Gland Pharma IPO
| Please check below or visit here to check allotment status of Gland Pharma IPO |
Frequently Asked Questions (FAQ)
| Q. How to Apply for IPO ? A. IPO can be applied Online and Offline mode. Online: a) Via Net banking of Bank website b) Via Stock brokers portal Offline: a) Collect application forms from Brokers > Fill demat details & UPI > Submit to any broker across India. b) Download forms from NSE/BSE website > Fill demat details & UPI > Submit to any broker across India. |
| Q. How to register for BHIM UPI? UPI is made mandatory by SEBI to apply for IPO's. To educate investors National Payment Corporation of India (NPCI) has come out with the useful video. This video educates on how to download BHIM UPI app and its process to register. Source: NPCI |
| What is UPI based ASBA Process ? To educate people to apply for IPO's National Payment Corporation of India (NPCI) has come out with the useful video. This video educates consumers on how the IPO process works and how subscribing for IPOs via BHIM UPI helps reduce the time and effort one needs to take for the same. Source: NPCI |
| Q3? Ans Source: NPCI |
Posts
0 Comments